Takeda Pharmaceutical Company Limited

Takeda Establishes Takeda Pharmaceuticals Mexico, S.A. de C.V. Expanding Presence in North America [Press Release]
PRNewswire | 21 days 13 hours 9 minutes ago
...Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc., and Takeda Global Research & Development...Inc., are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical...

Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity [Press Release]
PRNewswire | 23 days 4 hours 39 minutes ago
...Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that they have entered...president & chief executive officer, Takeda Pharmaceutical Company Limited. "Both Amylin and Takeda have extensive experience in the...

Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes [Press Release]
PRNewswire | 89 days 3 hours 8 minutes ago
...Japan, Aug. 28 /PRNewswire/ --Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development...Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company...

Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe [Press Release]
PRNewswire | 55 days 2 hours 37 minutes ago
...Japan, Oct. 1 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish...2009 CONTACT: Seizo Masuda of Takeda Pharmaceutical Company Limited,+81-3-3278-2037 (Office...

Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes [Press Release]
PRNewswire | 82 days 3 hours 7 minutes ago
...Japan, Sept. 4 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly...Center, Inc., are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company...

Takeda San Francisco Enters Into A Sponsored Research Agreement With UCSF [Press Release]
PRNewswire | 64 days 18 hours 36 minutes ago
...a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, announced today that it has entered...as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellenceand...

Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences [Press Release]
PRNewswire | 43 days 13 hours 9 minutes ago
...of Biomedical Sciences, Newark, NJ. Takeda San Francisco, Inc. (TSF), established...November 2007 as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, is Takeda's Biologics Center of Excellenceand Antibody...

Affymax and Takeda Announce Hematide Publication in the New England Journal of Medicine [Press Release]
Business Wire | 20 days 12 hours 9 minutes ago
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from a Phase 2 clinical trial of Hematide™ showing that Hematide increased hemoglobin and reduced or eliminated the need for blood transfusion in most patients with erythropoietin-induced pure red cell aplasia (PRCA). The data were published in the 5th November 2009 issue of the New England Journal of Medicine.

Affymax and Takeda Announce Preliminary Phase 2 Data Demonstrated That Hematide Increased Hemoglobin in Dialysis Patients [Press Release]
Business Wire | 25 days 16 hours 9 minutes ago
Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients. This is the first reported data from an open-label, controlled comparative study of once-monthly Hematide compared to three times per week epoetin alfa...

North Chicago High School Receives Facelift With the Help of More Than 325 Takeda Employee Volunteers [Press Release]
PRNewswire | 103 days 21 hours 7 minutes ago
...Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical...

Affymax Reports Third Quarter 2009 Financial Results [Press Release]
Business Wire | 20 days 21 hours 39 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million compared to a net loss of $26.2 million for the third quarter of 2008.

New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone [Press Release]
PRNewswire | 41 days 7 hours 35 minutes ago
...Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical...

Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program [Press Release]
Business Wire | 14 days 21 hours 9 minutes ago
Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide™, has completed its final scheduled review and has informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. While no additional meetings are planned, the DMC, under its charter, can request additional information regarding the studies at any t...

ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout [Press Release]
PRNewswire | 38 days 8 hours 9 minutes ago
PHILADELPHIA, Oct. 17 /PRNewswire/ -- Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC(R) (febuxostat) treatment.